supp.fit

Saw Palmetto: study protocols

48 study groups say how much Saw Palmetto participants took a day. These are the doses the studies gave. They are not a recommendation.

Saw Palmetto: what the research found →

Dose per serving from products

1,524 products in our catalogue print how much Saw Palmetto a serving holds.

Most common: 250 mg to 500 mg, 43% of 1,524 products.

Dose per servingProducts
10 mg or less
39
10 mg to 25 mg
64
25 mg to 50 mg
77
50 mg to 100 mg
194
100 mg to 250 mg
326
250 mg to 500 mg
651
500 mg to 1 g
143
over 1 g
30

Dose per serving from research

48 study groups in 37 studies say how much Saw Palmetto participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 mg to 500 mg, 88% of 48 study groups.

Daily doseStudy groups
100 mg to 250 mg
5
250 mg to 500 mg
42
over 500 mg
1

Commonly used together

12 of 48 study groups took Saw Palmetto with something else, but nothing that 3 or more different studies gave.

48 study groups

Study
Serenoa repens (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia
2010 · G1 · Men with benign prostatic hyperplasia who were candidates for transurethral resection of the prostate or open prostatectomy; age not reported
320 mg60 days72
A detailed safety assessment of a saw palmetto extract
2008 · saw palmetto extract · Men aged 50 years or older with at least moderately severe lower urinary tract symptoms and benign prostatic hyperplasia
320 mg1 year—
The Use of a Combination of Vaccinium Macracarpon, Lycium barbarum L. and Probiotics (Bifiprost®) for the Prevention of Chronic Bacterial Prostatitis: A Double-Blind Randomized Study
2019 · Group B · Men with NIH type II chronic bacterial prostatitis and recurrent enterobacteriaceae infections
320 mg24 weeks—
Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®)
2014 · Group B (antibiotic and supplement) · Adult men aged 19–54 with chronic bacterial prostatitis
320 mg30 days77
The Use of a Combination of Vaccinium Macracarpon, Lycium barbarum L. and Probiotics (Bifiprost®) for the Prevention of Chronic Bacterial Prostatitis: A Double-Blind Randomized Study
2019 · Group A · Men with NIH type II chronic bacterial prostatitis and recurrent enterobacteriaceae infections
320 mg24 weeks—
Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study
2002 · Permixon · Men with symptomatic benign prostatic hyperplasia (I-PSS ≥10); age not reported
320 mg1 year350
[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]
2002 · Permixon · Men with symptomatic benign prostatic hyperplasia and I-PSS ≥10
320 mg1 year350
Safety and toxicity of saw palmetto in the CAMUS trial
2013 · Saw palmetto (SP) arm · Men aged 45 years or older with lower urinary tract symptoms (AUASI score 8–24)
320 mg72 weeks176
The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial
2021 · Serenoa repens group · Men aged 18–50 with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)
320 mg12 weeks152
Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
2013 · SR group · Men with lower urinary tract symptoms due to benign prostatic hyperplasia
320 mg26 weeks97
Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
2013 · TAM + SR group · Men with lower urinary tract symptoms due to benign prostatic hyperplasia
320 mg26 weeks81
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis
2004 · Permixon group · Adults with severe lower urinary tract symptoms (IPSS >19) and benign prostatic hyperplasia
320 mg1 year65
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]
2004 · Permixon group · Adults with severe lower urinary tract symptoms (IPSS >19) and benign prostatic hyperplasia
320 mg1 year65
Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study
2015 · TAM+SR group · men with symptomatic benign prostatic hyperplasia (IPSS ≥10)
320 mg1 year60
[A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue]
2019 · Group II · Patients with benign prostatic hyperplasia associated with chronic inflammation; age and sex not further specified
320 mg90 days51
Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome
2024 · group 3 (Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility
320 mg90 days50
Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome
2024 · group 5 (tadalafil/Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility
320 mg90 days50
An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: results from the IDIProst® Gold Study
2013 · Serenoa repens · Men aged 45–71 with LUTS due to BPH and erectile dysfunction
320 mg90 days46
Beneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
2022 · SPE treatment (active) group · Women older than 50 years with frequent urination, nocturia, and/or urgency for at least 2 months; urinary symptoms did not require medical treatment
320 mg12 weeks38
Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments
2019 · Serenoa repens group · Men aged 18–70 with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)
320 mg6 weeks34
Beneficial effects of saw palmetto (Serenoa repens) fruit extract on the urinary symptoms of healthy Japanese adults with possible lower urinary tract symptoms: A randomized, double-blind, placebo-controlled study
2025 · SPE group · Healthy Japanese men and women aged 50 years or older with concerns about frequent urination
320 mg12 weeks33
[Efficacy and safety of № I Empirical Prescription for Chronic Prostatitis in the treatment of type Ⅲ refractory chronic prostatitis]
2018 · control group · Adults with type III refractory chronic prostatitis and damp-heat/blood-stasis syndrome; age and sex not reported
320 mg8 weeks23
BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay
2003 · Permixon group · Men with BPH; mean age 65.7 years
320 mg90 days12
Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens
1999 · one 160-mg capsule twice daily [BID] · Outpatients with symptomatic benign prostatic hyperplasia; age and sex not stated
320 mg90 days—
The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study
2019 · HESr · Patients with histologically confirmed prostatic inflammation; age and sex not specified
320 mg26 weeks—
Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study
2026 · Alfuzosin plus HESr · Treatment-naïve men with moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia, IPSS > 7 and prostate volume > 30 cc
320 mg1 year—
[A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue]
2019 · Group I · Patients with benign prostatic hyperplasia associated with chronic inflammation; age and sex not further specified
320 mg90 days51
Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome
2024 · group 6 (L-carnitine/Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility
320 mg90 days50
Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome
2024 · group 7 (tadalafil/L-carnitine/Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility
320 mg90 days50
The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results
2025 · active treatment · Healthy men and women aged 25–65 with self-perceived thinning hair
160 mg90 days40
The Safety and Efficacy of a Novel Saw Palmetto (Serenoa repens) Extract for Promoting Hair Growth in Adults With Self-Perceived Thinning Hair: 180-Day Results
2026 · active treatment · Healthy men and women aged 25–65 with self-perceived hair thinning
160 mg180 days40
Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens
1999 · two 160-mg capsules once daily (OD) · Outpatients with symptomatic benign prostatic hyperplasia; age and sex not stated
160 mg90 days—
The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens
2002 · Two 80-mg tablets twice daily · Adult men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
160 mg26 weeks—
The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens
2002 · Two 80-mg tablets three times daily · Adult men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
240 mg26 weeks—
Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin
2006 · PRO 160/120 (Prostagutt forte) group · Elderly out-patients with lower urinary tract symptoms caused by benign prostatic hyperplasia and initial I-PSS score of at least 13
320 mg60 weeks—
Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial
2005 · PRO 160/120 · Elderly men with lower urinary tract symptoms caused by benign prostatic hyperplasia
320 mg48 weeks129
Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial
2005 · PRO 160/120 after placebo · Elderly men with lower urinary tract symptoms caused by benign prostatic hyperplasia, initially assigned to placebo
320 mg24 weeks128
Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial
2007 · PRO 160/120 group and all patients during the open-label follow-up · Elderly men with moderate or severe lower urinary tract symptoms caused by benign prostatic hyperplasia
320 mg96 weeks—
Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A Real-Life, Multicenter, Randomized, Assessor-Blinded Trial on 225 Subjects
2025 · Group A (drug treatment and dietary supplementation) · Adults with mild-to-severe androgenic alopecia or female androgenic alopecia; men aged over 18 years and women of age appropriate for treatment
320 mg26 weeks106
Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
2015 · HESr · Men aged 45–85 with benign prostatic hyperplasia-related lower urinary tract symptoms
320 mg90 days102
Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients
1992 · Serenoa repens extract group · Patients with benign prostatic hypertrophy who had not previously been treated; age and sex not stated
480 mg90 days18
[Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon]
2004 · Permixon, 3 months · Patients with benign prostatic hyperplasia; age and sex details not reported
320 mg90 days12
[Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon]
2004 · Permixon, 6 months · Patients with benign prostatic hyperplasia; age and sex details not reported
320 mg26 weeks12
[Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon]
2004 · Permixon, 12 months · Patients with benign prostatic hyperplasia; age and sex details not reported
320 mg1 year12
Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia
2005 · SR-treated group · Men with symptomatic benign prostatic hyperplasia
320 mg90 days12
[Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate]
2004 · experimental group · Patients with benign prostatic hyperplasia undergoing transurethral resection of the prostate; age and sex details not reported
320 mg8 weeks—
Endocrine and lipid responses to chronic androstenediol-herbal supplementation in 30 to 58 year old men
2001 · AND-HB · Healthy men aged 30–58 years
480 mg4 weeks28
Effects of androstenedione-herbal supplementation on serum sex hormone concentrations in 30- to 59-year-old men
2001 · DION · Healthy men aged 30–59 years
540 mg4 weeks28